Entries by moonbase alpha

Mission Therapeutics Appoints Scientific Advisory Board

Cambridge, UK – 27 June 2017 – Mission Therapeutics, a drug discovery and development company focused on selectively targeting deubiquitylating enzymes (DUBs) to treat serious diseases including mitochondrial diseases, neurodegeneration, inflammation and cancer, today announced the formation of its inaugural Scientific Advisory Board (SAB). Mission’s co-founder and CSO, Professor Steve Jackson, FRS, FMedSci will chair […]

Mission Therapeutics nominated as Biotech and Money 2017 Awards Double Finalist

Cambridge, UK – 9 June 2017 – Mission Therapeutics, a drug discovery and development company focused on selectively targeting deubiquitylating enzymes (DUBs) to treat cancer, neurodegenerative and other diseases, has been announced as a finalist in two categories for the Biotech and Money 2017 Awards. The Biotech and Money 2017 Awards celebrate funding, finance and […]

Mission Therapeutics and University of Oxford Awarded Research Grant from the Michael J. Fox Foundation

Collaborative team to progress novel USP30 inhibitors to develop potential therapies for Parkinson’s disease CAMBRIDGE, UK – 11 April 2017 – On World Parkinson’s day, Mission Therapeutics, a drug discovery and development company focused on selectively targeting deubiquitylating enzymes (DUBs) to treat neurodegenerative diseases, cancer and other diseases with high unmet medical need, announced that […]

Mission Therapeutics Appoints Dr Anne Phelan as Senior Vice President, Head of Discovery Research

CAMBRIDGE, UK – 20 March 2017 – Mission Therapeutics, a drug discovery and development company focused on selectively targeting deubiquitylating enzymes (DUBs) to treat cancer, neurodegenerative and other diseases, announced the appointment of Dr Anne Phelan as Senior Vice President, Head of Discovery Research, effective 20 March 2017. Dr Phelan has spent over 20 years […]

Mission Therapeutics Appoints Colin Goddard as Chairman

Michael Moore Transitions to Deputy Chairman CAMBRIDGE, UK – 5 December 2016 – Mission Therapeutics, a drug discovery and development company focused on selectively targeting deubiquitylating enzymes (DUBs) to treat cancer, neurodegenerative and other diseases, announces that Dr Colin Goddard has been appointed as non-executive Chairman, effective January 1st 2017. Dr Colin Goddard joined the […]

Mission Therapeutics to Attend and Present at Conferences in October and November 2016

CAMBRIDGE, UK – 13 October 2016 – Mission Therapeutics, a drug discovery and development company focused on selectively targeting deubiquitylating enzymes to treat cancer, neurodegenerative and other diseases, today announced that the company is scheduled to attend the following events: (1) ELRIG Drug Discovery 2016 13-14 October 2016, ACC, Liverpool, UK The Drug Discovery meeting […]

Dr Michael Koslowski listed in the top 20 translational researchers

CAMBRIDGE, UK – 6 October 2016 – Mission Therapeutics, a drug discovery and development company focused on selectively targeting deubiquitylating enzymes to treat cancer, neurodegenerative and other diseases, is pleased to announce that its Chief Medical Officer, Dr Michael Koslowski has been listed as one of the 20 top translational researchers of 2015 in Nature Biotechnology. […]

Mission Therapeutics wins ‘One to Watch’ Private UK Life Science Company of the Year

CAMBRIDGE, UK – 7 September 2016 – Mission Therapeutics, a drug discovery and development company focused on selectively targeting deubiquitylating enzymes to treat cancer, neurodegenerative and other diseases, is pleased to announce it has won the “One to Watch Private UK Life Science Company of the Year” Award at the Biotech & Money 2016 Awards […]

Mission Therapeutics to Attend and Present at Conferences in June and July 2016

CAMBRIDGE, UK – 3 June 2016 – MISSION Therapeutics, a drug discovery and development company focused on selectively targeting deubiquitylating enzymes to treat cancer, neurodegenerative and other diseases, today announced that the company is scheduled to attend the following events: (1) American Society of Clinical Oncology (ASCO) Annual Meeting, 3–7 June 2016, McCormick Place, Chicago, […]

Mission Therapeutics to Attend and Present at Conferences in May 2016

CAMBRIDGE, UK – 4 May 2016 – MISSION Therapeutics, a drug discovery and development company focused on selectively targeting deubiquitylating enzymes to treat cancer, neurodegenerative and other diseases, today announced that the company is scheduled to attend the following events: (1) Mitochondrial Medicine: Developing New Treatments for Mitochondrial Disease conference, 4 – 6 May, Wellcome […]